Digestive Diseases and Sciences

, Volume 55, Issue 10, pp 2965–2970 | Cite as

The Association Between a Functional CYP1A1 Polymorphism and Colorectal Neoplasia Risk in Post Menopausal Women

  • Dayna S. Early
  • Feng Gao
  • Christina Y. Ha
  • Anne Nagler
  • Elizabeth Cole
  • Elizabeth Gorbe
  • Nicola Napoli
  • Reina Armamento-Villareal
Original Article



The impact of estrogen on risk of colorectal neoplasia is uncertain. Carriers of the AA and CA genotype allele of the C4887A polymorphism of the CYP1A1 gene have enhanced estrogen metabolism relative to carriers of the CC genotype.


This study examined whether this genetic marker of enhanced estrogen catabolism segregated with colorectal neoplasia (CRN) in postmenopausal women.


We enrolled hormone negative postmenopausal women having screening or surveillance colonoscopy. Demographic and medical data were gathered. Blood was collected and analyzed for CYP1A1 polymorphisms of the C4887A allele by PCR–RFLP. Colonoscopy and pathology data were gathered from hospital databases.


One hundred sixty-eight women were enrolled in the study. Twenty-one subjects (12.5%) carried at least one A allele, and 147 subjects (87.5%) carried the CC alleles for the C4887A polymorphism of the CYP1A1 gene. Seventy subjects (41.7%) had CRN and 98 subjects (58.3%) did not have CRN. Of the subjects who carried the A allele, 57% had CRN as compared to 39% of those who carried the CC allele; the association was not statistically significant (P = 0.16). In a multivariate logistic regression analysis, age, BMI, current tobacco use, and first degree relative with CRN were independent risk factors for CRN but the C4887A polymorphisms remained not statistically significant (P = 0.35).


Carriers of the A allele of the C4887A polymorphism have enhanced estrogen catabolism and lower free estradiol. Our results suggest, however, that inherent estrogen metabolism as determined by C4887A polymorphisms is not associated with CRN risk.


Colorectal neoplasia Postmenopausal Estrogen Screening CYP polymorphisms 



The authors wish to thank Donna Walsh RN, Claudia Westerhold-McDaniel CRNA, and the endoscopy center nurses for their assistance with phlebotomy. Grant support: This study was supported by the Washington University in St. Louis Digestive Diseases Research Core Center (NIH Grant # 5P30 DK052574).


  1. 1.
    Slattery ML, et al. Body mass index and colon cancer: an evaluation of the modifying effects of estrogen (United States). Cancer Causes Control. 2003;14(1):75–84.CrossRefPubMedGoogle Scholar
  2. 2.
    Chlebowski RT, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med. 2004;350(10):991–1004.CrossRefPubMedGoogle Scholar
  3. 3.
    Anderson GL. The women’s health initiative steering committee. JAMA. 2004;291:1701–1712.CrossRefPubMedGoogle Scholar
  4. 4.
    Hebert-Croteau N. A meta analysis of hormone replacement therapy and colon cancer in women. Cancer Epidemiol Biomarkers Prev. 1998;7:653–659.PubMedGoogle Scholar
  5. 5.
    Grodstein F, Newcomb PA, Stampfer M. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med. 1999;106:574–582.CrossRefPubMedGoogle Scholar
  6. 6.
    Konstantinopoulos PA. Estrogen receptor beta (ER beta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour’s dedifferentiation. Eur J Cancer. 2003;39:1251–1258.CrossRefPubMedGoogle Scholar
  7. 7.
    Campbell-Thompson M. Expression of estrogen receptor subtypes and ER beta isoforms in colon cancer. Cancer Res. 2001;61:632–640.PubMedGoogle Scholar
  8. 8.
    Carothers AM, et al. 2-Methoxyestradiol induces p53-associated apoptosis of colorectal cancer cells. Cancer Lett. 2002;187(1–2):77–86.CrossRefPubMedGoogle Scholar
  9. 9.
    Calle EE, et al. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst. 1995;87:517–523.CrossRefPubMedGoogle Scholar
  10. 10.
    Folsom AR, et al. Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am J Public Health. 1995;85(8):1128–1132.CrossRefPubMedGoogle Scholar
  11. 11.
    Furner SE, et al. A case-control study of large bowel cancer and hormone exposure in women. Cancer Res. 1989;49(17):4936–4940.PubMedGoogle Scholar
  12. 12.
    Hammond CB, et al. Effects of long-term estrogen replacement therapy. I. Metabolic effects. Am J Obstet Gynecol. 1979;133(5):525–536.PubMedGoogle Scholar
  13. 13.
    Jacobs EJ, White E, Weiss NS. Exogenous hormones, reproductive history, and colon cancer (Seattle, Washington, USA). Cancer Causes Control. 1994;5(4):359–366.CrossRefPubMedGoogle Scholar
  14. 14.
    Kampman E, et al. Hormone replacement therapy, reproductive history, and colon cancer: a multicenter, case-control study in the United States. Cancer Causes Control. 1997;8(2):146–158.CrossRefPubMedGoogle Scholar
  15. 15.
    Nachtigall LE, et al. Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol. 1979;54(1):74–79.CrossRefPubMedGoogle Scholar
  16. 16.
    Newcomb PA, Storer BE. Postmenopausal hormone use and risk of large-bowel cancer. [Erratum appears in J Natl Cancer Inst 1995 Sep 20;87(18):1416]. J Natl Cancer Inst. 1995;87(14):1067–1071.CrossRefPubMedGoogle Scholar
  17. 17.
    Paganini-Hill A. Estrogen replacement therapy and colorectal cancer risk in elderly women. Dis Colon Rectum. 1999;42(10):1300–1305.CrossRefPubMedGoogle Scholar
  18. 18.
    Persson I, et al. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy—long-term follow-up of a Swedish cohort. Int J Cancer. 1996;67(3):327–332.CrossRefPubMedGoogle Scholar
  19. 19.
    Potter JD, McMichael AJ. Large bowel cancer in women in relation to reproductive and hormonal factors: a case-control study. J Natl Cancer Inst. 1983;71(4):703–709.PubMedGoogle Scholar
  20. 20.
    Risch HA, Howe GR. Menopausal hormone use and colorectal cancer in Saskatchewan: a record linkage cohort study. Cancer Epidemiol Biomarkers Prev. 1995;4(1):21–28.PubMedGoogle Scholar
  21. 21.
    Troisi R, et al. A prospective study of menopausal hormones and risk of colorectal cancer (United States). Cancer Causes Control. 1997;8(2):130–138.CrossRefPubMedGoogle Scholar
  22. 22.
    Weiss NS, Daling JR, Chow WH. Incidence of cancer of the large bowel in women in relation to reproductive and hormonal factors. J Natl Cancer Inst. 1981;67(1):57–60.PubMedGoogle Scholar
  23. 23.
    Fernandez E, et al. Hormone replacement therapy and risk of colon and rectal cancer. Cancer Epidemiol Biomarkers Prev. 1998;7(4):329–333.PubMedGoogle Scholar
  24. 24.
    Badawi AF, Cavalieri EL, Rogan EG. Role of human cytochrome P450 1A1, 1A2, 1B1, and 3A4 in the 2-, 4-, and 16alpha-hydroxylation of 17beta-estradiol. Metabolism. 2001;50:1001–1003.CrossRefPubMedGoogle Scholar
  25. 25.
    Martucci CP, Fishman J. P450 enzymes of estrogen metabolism. Pharmacol Ther. 1993;57:237–257.CrossRefPubMedGoogle Scholar
  26. 26.
    Napoli N, et al. Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density. J Bone Miner Res. 2005;20(2):232–239.CrossRefPubMedGoogle Scholar
  27. 27.
    Mukhopadhyay T, Roth JA. Induction of apoptosis in human lung cancer cells after wild-type p53 activation by methoxyestradiol. Oncogene. 1997;14(3):379–384.CrossRefPubMedGoogle Scholar
  28. 28.
    Schumacher G, et al. Potent antitumor activity of 2-methoxyestradiol in human pancreatic cancer cell lines. Clin Cancer Res. 1999;5(3):493–499.PubMedGoogle Scholar
  29. 29.
    Qiu Y, Langman MJ, Eggo MC. Targets of 17beta-oestradiol-induced apoptosis in colon cancer cells: a mechanism for the protective effects of hormone replacement therapy? J Endocrinol. 2004;181(2):327–337.CrossRefPubMedGoogle Scholar
  30. 30.
    Takahashi Y, et al. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995;55(18):3964–3968.PubMedGoogle Scholar
  31. 31.
    Hsu HH, et al. Over-expressed estrogen receptor-alpha up-regulates hTNF-alpha gene expression and down-regulates beta-catenin signaling activity to induce the apoptosis and inhibit proliferation of LoVo colon cancer cells. Mol Cell Biochem. 2006;289(1–2):101–109.CrossRefPubMedGoogle Scholar
  32. 32.
    Xu X, Thomas ML. Estrogen receptor-mediated direct stimulation of colon cancer cell growth in vitro. Mol Cell Endocrinol. 1994;105(2):197–201.CrossRefPubMedGoogle Scholar
  33. 33.
    Di Domenico M, et al. Estradiol activation of human colon carcinoma-derived Caco-2 cell growth. Cancer Res. 1996;56(19):4516–4521.PubMedGoogle Scholar
  34. 34.
    Napoli N, Armamento-Villareal R. Estrogen hydroxylation in osteoporosis. Adv Clin Chem. 2007;43:211–227.CrossRefPubMedGoogle Scholar
  35. 35.
    Esteller M, et al. Germ line polymorphisms in cytochrome-P450 1A1 (C4887 CYP1A1) and methylenetetrahydrofolate reductase (MTHFR) genes and endometrial cancer susceptibility. Carcinogenesis. 1997;18(12):2307–2311.CrossRefPubMedGoogle Scholar
  36. 36.
    Krajinovic M, et al. Genetic susceptibility to breast cancer in French-Canadians: role of carcinogen-metabolizing enzymes and gene-environment interactions. Int J Cancer. 2001;92(2):220–225.CrossRefPubMedGoogle Scholar
  37. 37.
    Napoli N, Mumm S, Armamento-Villareal R. Author reply. CYP1A1: Ethnic and population differences in allelic frequencies and interpretation of bone biology studies. J Bone Miner Res. 2006;21(12):1960–1961.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Dayna S. Early
    • 1
  • Feng Gao
    • 3
  • Christina Y. Ha
    • 1
  • Anne Nagler
    • 4
  • Elizabeth Cole
    • 1
  • Elizabeth Gorbe
    • 1
  • Nicola Napoli
    • 2
  • Reina Armamento-Villareal
    • 2
  1. 1.Division of GastroenterologyWashington University in St. LouisSt. LouisUSA
  2. 2.Division of Bone and Mineral DiseasesWashington University in St. LouisSt. LouisUSA
  3. 3.Division of BiostatisticsWashington University in St. LouisSt. LouisUSA
  4. 4.Department of MedicineWashington University in St. LouisSt. LouisUSA

Personalised recommendations